STAT

•

ช่องรายการ • รายการ 2 รายการ

ข่าว

ข่าว

อัปเดตทุกสองสัปดาห์
ธุรกิจ

ธุรกิจ

อัปเดตทุกสัปดาห์

14/11/2567

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so we oblige with a tick-tock on what went down between Amgen and a Wall Street analyst who noted a possible safety issue with the obesity drug candidate MariTide.

14/11/2567

•

30 นาที
10/12/2568

The revolution in dementia care is just beginning

When Jason Karlawish started working with dementia patients in the late ’90s, there often wasn’t much he could offer them. “I gave them a diagnosis,” he told me on this week’s episode of the “First Opinion Podcast,” but had limited medications to prescribe. Now Karlawish — who is STAT’s Neurotransmissions columnist; a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania; co-director of the Penn Memory Center; and executive producer of the “Age of Aging” podcast — says a revolution is taking place in dementia care, thanks to diagnostics that are removing uncertainty and treatments that actually have some effect.

10/12/2568

•

40 นาที
21/11/2567

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

21/11/2567

•

35 นาที
09/01/2568

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

09/01/2568

•

33 นาที
27/02/2568

343: Turbulence at the FDA, Bluebird Bio's sale and young biotech VCs

It’s a STAT reporter two-fer guest episode. First, Lizzy Lawrence joins from D.C. to dish on the upheaval and drama taking place at the FDA. Then, we chat with Jason Mast about Bluebird Bio, its fire sale to private equity and what lies ahead for the unsettled world of genetic medicines. Before those discussions, Allison provides some insight into the “new kids” on the biotech VC block.

27/02/2568

•

32 นาที
20/02/2568

342: FDA cuts, zombie biotechs, and too much weight loss?

Mizuho analyst Jared Holz joins to discuss Adam's column on biotech's dark period. We also talk about Elaine's latest article on the push for greater and greater weight loss from obesity drugs, along with developments at Solid Biosciences and federal job cuts.

20/02/2568

•

41 นาที
15/01/2568

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the industry.

15/01/2568

•

59 นาที
24/04/2568

350: Pharma tariffs, and a 'sunshine day' for biotech stocks

How did Ireland become a hotspot for pharmaceutical manufacturing? What are the products that will come out of Flagship's latest startup centered around "preemptive medicine"? And who among the co-hosts is the best singer? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb's schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more. We also bring on STAT's European correspondent Drew Joseph to talk about the growth of pharma manufacturing in Ireland and how U.S. tariffs would impact global drug supply.

24/04/2568

•

32 นาที
07/11/2567

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

To dig into how the election results could affect all things biopharma, we brought on three guests for this episode: Lizzy Lawrence, STAT’s FDA reporter, Baird analyst Brian Skorney, and longtime biotech executive Daphne Zohar.

07/11/2567

•

39 นาที
13/03/2568

345: The sudden withdrawal of a CDC nominee and what went wrong with Covid policies

We bring on our colleague Sarah Owermohle to discuss the White House's sudden move to withdraw the nomination of Dave Weldon as its pick to run the CDC just hours before Weldon's confirmation hearing. It's also the five-year anniversary of the Covid-19 pandemic. We chat with Princeton political scientist Frances Lee about a new book she co-authored that offers an unflinching assessment of the U.S. policy responses to the pandemic and raises some provocative questions about what went wrong.

13/03/2568

•

31 นาที

Voices from the frontiers of health and medicine

เว็บไซต์